PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503686-26-00

Enrollment

Registered

2024-03-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Pulmonary Fibrosis (PPF)

Brief summary

FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation

Detailed description

Activity thresholds for positive FAPI-PET/CT confirming active fibrosis,, Correlation between baseline FAPI activity and ILD extent/degree of reticulation on HRCT as well as serum biomarkers for inflammation

Interventions

DRUG[18F]-AlF-FAPI-74

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation	—

Secondary

Measure	Time frame
Activity thresholds for positive FAPI-PET/CT confirming active fibrosis,, Correlation between baseline FAPI activity and ILD extent/degree of reticulation on HRCT as well as serum biomarkers for inflammation	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026